List of Excipients in Branded Drug READYPREP CHG

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Medline Industries LP	READYPREP CHG	chlorhexidine gluconate 2%	53329-244	BENZALKONIUM CHLORIDE
Medline Industries LP	READYPREP CHG	chlorhexidine gluconate 2%	53329-244	DIMETHICONE 350
Medline Industries LP	READYPREP CHG	chlorhexidine gluconate 2%	53329-244	GLYCERIN
Medline Industries LP	READYPREP CHG	chlorhexidine gluconate 2%	53329-244	ISOPROPYL ALCOHOL
Medline Industries LP	READYPREP CHG	chlorhexidine gluconate 2%	53329-244	PROPYLENE GLYCOL

ReadyPrep CHG Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 4, 2026

ReadyPrep CHG is a chlorhexidine gluconate (CHG) and isopropyl alcohol (IPA) antiseptic skin-preparation product used before invasive procedures. Its commercial value is driven less by conventional excipient innovation than by concentration control, rapid drying, applicator engineering, packaging, regulatory compliance, and institutional procurement. The core formulation is generally 2% chlorhexidine gluconate in 70% isopropyl alcohol, with purified water and packaging components supporting delivery and stability.[1]

The formulation has limited composition-of-matter exclusivity. Commercial barriers are more likely to arise from applicator design, sterile or low-bioburden packaging, manufacturing controls, brand contracts, and clinical-use claims than from the CHG-IPA mixture itself.

What is ReadyPrep CHG and how is it formulated?

ReadyPrep CHG is a topical antiseptic preparation containing chlorhexidine gluconate as the antimicrobial active and isopropyl alcohol as the rapid-acting solvent and antimicrobial co-active.

Component	Typical role	Commercial relevance
Chlorhexidine gluconate	Persistent antimicrobial active	Provides residual skin antisepsis
Isopropyl alcohol, typically 70% v/v	Rapid antimicrobial action and solvent	Drives fast drying and broad microbial reduction
Purified water	Vehicle and concentration adjustment	Controls solvent balance and product usability
Applicator substrate	Delivers the formulation to skin	Can affect dose uniformity, wetting, drying, and waste
Packaging system	Maintains product integrity	Important for evaporation control, sterility claims, and shelf life

The formulation must balance several technical requirements. Excessive alcohol loss can reduce antimicrobial performance and alter the labeled concentration. Insufficient wetting can produce incomplete skin coverage. Excessive residual liquid can increase drying time and create operating-room fire-safety concerns.

What excipients are used in ReadyPrep CHG?

The principal non-active component is water used to adjust the alcohol concentration and provide the vehicle. The product’s commercial differentiation does not appear to depend on a complex excipient system such as surfactants, polymers, emulsifiers, preservatives, or penetration enhancers.

That simplicity is strategically important. It lowers formulation complexity but also limits opportunities to obtain strong composition patents. A competing manufacturer can usually develop a similar CHG-IPA formulation without reproducing proprietary intellectual property, provided it complies with applicable FDA requirements and does not copy protected packaging, labeling, or device features.

What is the excipient strategy for ReadyPrep CHG?

The excipient strategy is functional rather than therapeutic. Each non-active component supports one of four objectives: antimicrobial performance, skin coverage, drying behavior, or product stability.

Alcohol-water balance

The alcohol-water ratio is central to product performance. Isopropyl alcohol contributes rapid kill and evaporation. Water supports CHG solubility, formulation handling, and skin wetting. The formulation must preserve the labeled concentration throughout shelf life, including after exposure to temperature variation and headspace conditions.

Potential development work includes:

• tighter control of IPA concentration;
• reduced evaporation during storage;
• improved wetting of intact and difficult-to-cover skin surfaces;
• controlled drying time;
• lower odor and reduced skin stinging;
• compatibility with the applicator substrate and package seal.

These improvements may support formulation or manufacturing patents, but their patent strength depends on whether the product uses a genuinely unexpected technical effect rather than routine concentration optimization.

Substrate and delivery system

For a preoperative skin-preparation product, the applicator is often as important as the liquid formulation. The substrate must release CHG and IPA consistently, avoid linting, remain mechanically stable, and provide sufficient fluid volume for the intended body area.

Potential commercial improvements include:

• foam, sponge, swab, or textured applicator formats;
• controlled-dose applicators;
• larger-volume formats for orthopedic and cardiovascular procedures;
• smaller formats for catheter insertion and minor procedures;
• applicators designed to reduce hand contact;
• packaging that limits alcohol loss after opening;
• applicator geometry that improves coverage around joints, hair, and anatomical contours.

These features can produce stronger device, packaging, or combination-product claims than the base liquid composition.

Skin tolerability

CHG can cause irritation and, rarely, serious hypersensitivity reactions. FDA has required warnings for chlorhexidine-containing antiseptic products because of reports of severe allergic reactions.[2] Excipients or delivery changes that reduce pooling, limit unnecessary exposure, or improve controlled application may create commercial value.

A manufacturer should avoid adding excipients that create new sensitization, residue, flammability, or compatibility concerns. A simple formulation can be an advantage in hospitals that prefer predictable ingredient profiles.

What patents protect ReadyPrep CHG?

The core CHG-IPA composition is unlikely to provide broad exclusivity comparable to a novel small-molecule drug. Chlorhexidine, chlorhexidine gluconate, and alcohol-based antiseptic preparations have long histories of commercial use.

The likely intellectual-property categories are:

IP category	Likely strength	Typical subject matter
CHG-IPA composition	Low to moderate	Concentration ranges, solvent ratios, stability limits
Applicator design	Moderate to high	Dose delivery, substrate construction, handling, coverage
Packaging	Moderate	Seals, reservoirs, evaporation control, tamper evidence
Manufacturing process	Moderate	Filling, sterilization or bioburden control, assembly
Method of use	Low to moderate	Procedure-specific preparation methods or drying protocols
Branding and trade dress	Moderate	Product name, package appearance, institutional recognition
Trade secrets	Moderate	Filling parameters, supplier specifications, quality controls

A freedom-to-operate review should search patents assigned to the ReadyPrep manufacturer, its parent company, contract manufacturers, and applicator suppliers. The review should cover U.S. patents, published applications, continuations, foreign family members, and expired patent families.

How many patents cover ReadyPrep CHG?

A definitive patent count cannot be assigned from the product name alone. ReadyPrep CHG may be sold under a private-label, distributor, or contract-manufacturing structure in which the labeler, manufacturer, and IP owner are different entities.

The relevant search should use:

• the exact product name;
• the labeler and manufacturer shown in FDA databases;
• NDC and catalog numbers;
• CHG-IPA applicator patents;
• assignees associated with the manufacturer;
• packaging and medical-supply companies;
• patent families cited in related antiseptic products.

The absence of a prominent Orange Book listing would not mean that no patents exist. It would indicate only that the product is not relying on an FDA-listed drug patent in the same manner as an NDA product.

What is the FDA regulatory status of ReadyPrep CHG?

ReadyPrep CHG is a topical antiseptic product and may be regulated through a combination of drug, device, and institutional-use requirements depending on its formulation, labeling, applicator, and marketing claims.

FDA’s final rule for consumer antiseptic washes did not establish a broad over-the-counter monograph pathway for chlorhexidine gluconate products. FDA has required additional data for certain antiseptic active ingredients and has maintained safety warnings for CHG products.[2,3]

The regulatory assessment should distinguish among:

1. the liquid antiseptic drug;
2. the applicator or delivery device;
3. sterile versus nonsterile presentation;
4. professional-use versus consumer-use labeling;
5. surgical preparation claims versus general antiseptic claims;
6. drug listing and NDC status;
7. any NDA, ANDA, monograph, or enforcement-discretion basis.

What is the Orange Book status of ReadyPrep CHG?

ReadyPrep CHG should not be assumed to have an Orange Book patent listing. The Orange Book primarily lists approved drugs with approved applications and associated patent or exclusivity information. A topical antiseptic product marketed through a monograph, legacy, private-label, or other pathway may not have Orange Book-listed patents.[4]

The commercial consequence is direct: generic-entry analysis may depend more on product approval status, labeling, manufacturing compliance, and device compatibility than on Paragraph IV litigation.

When does ReadyPrep CHG lose exclusivity?

ReadyPrep CHG does not appear to have a conventional single-patent exclusivity date that determines market entry. Its competitive protection is more likely to be layered across:

• brand recognition;
• hospital contracts;
• distributor agreements;
• product qualification;
• applicator patents;
• packaging patents;
• manufacturing know-how;
• regulatory records;
• switching costs in clinical protocols.

Where no active blocking patent applies, competing CHG-IPA products can enter after meeting FDA requirements and demonstrating acceptable quality, labeling, and performance. The absence of a fixed patent cliff can increase competitive pressure because entry can occur incrementally through private-label products, regional suppliers, and alternate applicator formats.

What commercial opportunities exist for ReadyPrep CHG excipients and delivery systems?

The largest opportunities are in delivery and procurement economics rather than new active ingredients.

Procedure-specific formats

Hospitals buy skin-preparation products by procedure and use setting. Commercial opportunities include:

• catheter insertion kits;
• central-line bundles;
• orthopedic surgery formats;
• cardiac and vascular surgery formats;
• emergency-department applicators;
• outpatient and ambulatory-surgery packs;
• neonatal or pediatric presentations where permitted by labeling;
• smaller applicators for localized procedures.

A product with the same active ingredients can obtain a procurement advantage by reducing preparation time, minimizing waste, or improving coverage consistency.

Lower-waste packaging

Alcohol-based products are sensitive to evaporation and packaging integrity. Packaging that reduces loss during storage and improves single-use handling can support a differentiated product claim.

Relevant development targets include:

• lower residual volume;
• better seal integrity;
• optimized headspace;
• compact carton design;
• reduced plastic weight;
• recyclable components where compatible with alcohol and CHG;
• packaging that prevents premature applicator drying.

Packaging claims should be supported by shelf-life, transport, leakage, and extractables-and-leachables testing.

Contract manufacturing and private label

CHG-IPA products are suitable for private-label and contract-manufacturing models because the base formulation is comparatively standardized. Opportunity exists for manufacturers that can provide:

• validated filling and assembly;
• consistent applicator performance;
• scalable packaging;
• hospital-specific labeling;
• integrated procedure kits;
• reliable supply during shortages;
• competitive pricing against branded suppliers.

The principal barrier is qualification. Hospitals often require supplier audits, product testing, infection-control review, and purchasing-system integration before switching products.

Which companies are challenging ReadyPrep CHG?

Competition is likely to come from manufacturers and distributors selling alcohol-based CHG skin-preparation products, including branded surgical-preparation suppliers, generic antiseptic companies, private-label medical distributors, and procedure-kit manufacturers.

The most relevant competitive dimensions are:

Dimension	Competitive question
Active concentration	Does the product use 2% CHG in 70% IPA or another labeled concentration?
Applicator	Does it provide equal or better coverage and dose control?
Regulatory status	Is the product legally marketed for the same use?
Supply	Can the supplier support national hospital demand?
Price	Is acquisition cost lower after accounting for waste and labor?
Evidence	Does the product have relevant antimicrobial or clinical support?
Safety	Does labeling address CHG allergy and flammability risks?
Contracting	Can the supplier meet group-purchasing and distributor requirements?

What litigation and settlement risks affect ReadyPrep CHG?

The most likely disputes involve patent infringement, trade dress, false advertising, product liability, contract performance, and regulatory compliance. A Paragraph IV dispute is less likely unless the product is tied to an approved application with Orange Book-listed patents.

Potential litigation triggers include:

• copying a patented applicator;
• using a confusingly similar package design;
• making unsupported superiority claims;
• violating a hospital or distributor agreement;
• alleged failure to warn about CHG hypersensitivity;
• contamination, leakage, or inadequate dose delivery;
• inaccurate antimicrobial or drying claims.

Settlement agreements may restrict launch timing, labeling, supply territories, or use of specific applicator designs. Any transaction analysis should review litigation dockets, patent assignments, licensing records, and supplier agreements rather than relying only on the product label.

How strong is the ReadyPrep CHG patent estate?

The likely patent estate is stronger around delivery and packaging than around the liquid formulation.

A practical qualitative assessment is:

Asset	Assessment
Base CHG-IPA formulation	Limited blocking strength because the ingredients and general use are established
Narrow concentration or stability claims	Potentially useful but vulnerable to obviousness and prior-art challenges
Applicator engineering	Most promising area for enforceable differentiation
Procedure kits	Commercially valuable, but protection may depend on combination and workflow claims
Manufacturing process	Useful if difficult to reverse engineer and supported by process patents
Brand and contracts	Often more important commercially than formulation patents

Patent value should be measured against actual design-around options. A patent covering a specific applicator reservoir, substrate, or dose-control structure may block a premium product even when competitors can sell the same CHG-IPA liquid in another format.

What generic launch scenarios exist for ReadyPrep CHG?

Three launch scenarios are plausible.

Direct formulation competition

A competitor markets a comparable CHG-IPA preparation with a different brand, applicator, or private-label arrangement. This is the fastest route when no blocking patent or approval barrier applies.

Device-led substitution

A competitor uses a similar formulation but improves ergonomics, coverage, drying, waste, or kit integration. This approach can win contracts without directly competing on active-ingredient innovation.

Procurement-led entry

A distributor or group-purchasing organization introduces a lower-cost equivalent after product qualification. This can reduce pricing even if the incumbent retains strong clinical recognition.

Commercial entry risk is highest where hospital buyers perceive products as functionally interchangeable. Defensible differentiation requires documented performance, reliable supply, lower total cost, or a protected delivery system.

How does ReadyPrep CHG compare with alternative antiseptics?

CHG in alcohol is commonly selected because it combines rapid alcohol activity with CHG’s residual antimicrobial effect. Povidone-iodine products remain an important alternative, especially where CHG sensitivity, anatomical restrictions, or institutional protocols affect product selection.[5]

Attribute	CHG in alcohol	Povidone-iodine
Rapid activity	High	Generally slower
Residual activity	Persistent CHG effect	Less persistent
Flammability	Alcohol creates fire-safety requirements	Usually lower alcohol-related risk
Allergy concern	CHG hypersensitivity warning	Iodine-related concerns and contraindications
Formulation complexity	Relatively simple	Often aqueous or alcohol-containing variants
Patent differentiation	More likely in applicator and packaging	More likely in formulation, delivery, and claims

No product should be marketed as universally superior without clinical and regulatory support for the specific claim.

Key Takeaways

• ReadyPrep CHG is primarily a CHG-IPA antiseptic delivery product, not a complex excipient-driven drug.
• The likely formulation uses chlorhexidine gluconate, isopropyl alcohol, purified water, and an applicator system.
• Composition patents are likely weaker than patents covering applicators, packaging, manufacturing, and procedure kits.
• FDA status, labeling, NDC records, and marketing claims must be assessed separately from Orange Book patent listings.
• Paragraph IV risk appears less central than regulatory compliance, private-label entry, hospital qualification, and device design-around risk.
• The strongest commercial opportunities are controlled-dose applicators, lower-waste packaging, procedure-specific kits, private label, and supply-chain reliability.
• CHG hypersensitivity, alcohol flammability, evaporation, and dose uniformity are key technical and regulatory constraints.

FAQs About ReadyPrep CHG

Is ReadyPrep CHG a drug or a medical device?

The antiseptic liquid is a drug product, while the applicator may be regulated as a device or as part of a drug-device combination, depending on its design and claims.

Can a competitor make a 2% CHG in 70% IPA product?

Potentially, but the competitor must satisfy applicable FDA marketing, manufacturing, labeling, quality, and packaging requirements and avoid infringement of active delivery or packaging patents.

Are CHG-IPA formulations protected by formulation patents?

Some narrow patents may cover concentration ranges, stability, delivery systems, or manufacturing methods. The basic CHG-IPA concept has limited exclusivity because both components and their antiseptic use are established.

What is the main commercial risk to ReadyPrep CHG?

The main risk is substitution by lower-cost or better-designed products that provide equivalent antiseptic performance with improved applicator ergonomics, reduced waste, or stronger hospital-contract economics.

Can excipients improve ReadyPrep CHG?

Potentially, but the highest-value improvements may come from packaging and delivery engineering rather than adding new excipients. Any additive must be assessed for CHG compatibility, skin tolerability, flammability, residue, stability, and regulatory impact.

References

1. DailyMed. (n.d.). Chlorhexidine gluconate and isopropyl alcohol topical antiseptic product labeling. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2017). FDA warns about rare but serious allergic reactions with chlorhexidine gluconate.
3. U.S. Food and Drug Administration. (2016). Safety and effectiveness of consumer antiseptic washes; final rule. Federal Register, 81 Fed. Reg. 61106.
4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. Orange Book.
5. World Health Organization. (2016). Global guidelines for the prevention of surgical site infection. World Health Organization.